Ian S Maze, PhD
img_Ian S Maze
PROFESSOR | Neuroscience
PROFESSOR | Pharmacological Sciences
Research Topics
Addiction, Behavior, Chromatin, Depression, Drug Design and Discovery, Gene Expressions, Molecular Biology, Neuroscience
Multi-Disciplinary Training Area
Disease Mechanisms and Therapeutics (DMT), Neuroscience [NEU]
The Maze laboratory is focused on understanding the role of chromatin dynamics, nucleosomal turnover and histone modifications in the central nervous system during periods of transcriptional, synaptic and behavioral plasticity. Extended emphasis is placed on investigating the functions of novel neuronal specific/enriched histone modifications and ‘reader’ proteins, as well as their role in developmental neurological disorders (e.g. Down syndrome, autism) and adult psychiatric illness (major depressive disorder, substance use disorder, etc.). Current projects include the utilization of chromatin biochemical techniques, genome-wide sequencing analyses and transgenic/viral vector-based gene modification systems to investigate novel chromatin-based mechanisms of monoaminergic dysfunction in disease.  Search PubMed for publications

BS, The Ohio State University

PhD, Mount Sinai School of Medicine

Postdoctoral Fellowship, The Rockefeller University

2022

McKnight Brain Disorder Award

2021

Howard Hughes Medical Institute Investigator

2019

Dr. Harold and Golden Laport Basic Research Award

2019

Winner of Presidential Early Career Award for Scientists and Engineers (PECASE)

2017

Basil O’Connor Award

March of Dimes

2016

Sloan Foundation Fellowship in Neuroscience

2015

ACNP Travel Award

2015

MQ: Transforming Mental Health Research Fellowship Award

2014

NARSAD Young Investigator Award

2011

Terry A. Krulwich Dissertation Award, Mount Sinai School of Medicine

Predicting Depression Risk and Treatment Response Through Blood Chemistry: Ian Maze, Ph.D.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Maze during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.